• Report Outlines Planning Guidelines for Care During Mass Casualty Events
    Guidelines for officials on how to plan for delivering health and medical care in a mass casualty event are outlined in a new report from an expert panel convened by HHS’ Agency for Healthcare Research and Quality and Office of Public Health Emergency Preparedness. The ...More
    May 12, 2005 Posted in News
  • Physicians Support Imprisoned Texas Doctor
    A group of physicians and scientists expressed their support for Dr. Thomas C. Butler, jailed in 2003 on charges related to the disappearance of 30 vials of plague bacteria, in the June 1, 2005 issue of Clinical Infectious Diseases. Butler's appeal will be heard on June 8. ...More
    May 12, 2005 Posted in News
  • B. Braun to Offer FDA-Approved Ceftriaxone in the Duplex Drug-Delivery System
    BETHLEHEM, Pa. -- B. Braun Medical Inc. today announced that it received FDA approval for CefTRIaxONE in the DUPLEX® Drug Delivery System.  The availability of CefTRIaxONE, a standard intravenous antibiotic preparation, helps clinicians comply with Joint Commission on ...More
    May 10, 2005 Posted in News
  • Is the Vaccine Industry Ailing?
    Recent shortages of vaccines, most recently the flu vaccine during the past winter, are not short-term glitches—they reflect long-term problems in the vaccine industry. A variety of social, legal and economic forces have caused pharmaceutical companies to withdraw their ...More
    May 10, 2005 Posted in News
  • Employees Willing to Pay More for Greater Vaccine Benefits
    How much is it worth to you and your family to have a health insurance plan that covers the latest innovations in adult and childhood vaccines for certain types of cancer or even influenza and pneumonia? A new national Web-based study from the University of Michigan Health ...More
    May 10, 2005 Posted in News
  • NIAID Awards First $9 Million Using New Bioshield Authorities
    The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded 10 grants and two contracts totaling approximately $9 million to fund development of new therapeutics and vaccines against some of the most deadly ...More
    May 9, 2005 Posted in News
  • Oculus Announces FDA 501K Clearance of Microcyn Technology
    PETALUMA, Calif. -- Hoji Alimi, founder and president of Oculus Innovative Sciences, today announced that the company has received its first 510K clearance  from the Food and Drug Administration (FDA) to market Dermacyn™ Wound Care, formulated with Microcyn™ ...More
    May 9, 2005 Posted in News
  • Study Reports HAIs are on the Rise
    WASHINGTON, D.C. -- Infection control practitioners (ICPs) devote their careers to preventing healthcare-associated infections (HAI) by educating healthcare personnel on infection prevention measures, conducting infection surveillance, and reporting infection data to ...More
    May 9, 2005 Posted in News
  • Inhibitex Reports Favorable Results From Aurexis Phase II Trial for the Treatment of Staph Bloodstream Infections
    ATLANTA -- Inhibitex, Inc.  today reported top-line findings from its Phase II clinical trial of Aurexis for the adjunctive treatment of serious, life threatening Staphylococcus aureus (S. aureus) bloodstream infections in combination with antibiotics. Favorable ...More
    May 9, 2005 Posted in News
  • Two Studies Document Rise of Superbugs in the Environment
    As science gets wiser, so do the bugs. The rates of drug-resistant bacteria infecting patients in the community and in the hospital have been increasing steadily in recent years, according to two new studies in the June, 2005 15 issue of Clinical Infectious Diseases. Drug ...More
    May 9, 2005 Posted in News